Medical device and MedTech insights, news, tips and more

Philips Launches First Hand Held Heart Attack Diagnostic Device

May 31, 2016

Heart Attack

Royal Philips ($PHG) has made moves on a couple of fronts this week. It launched its heart attack test for its handheld diagnostic device after gaining a CE mark. And it also successfully executed an IPO for its lighting business that valued the company at almost $4 billion.

 Heart AttackPhilips sold 25% of Philips Lighting in the IPO to raise $839 million. The IPO also rose 8% in early trading, suggesting there may be enough investor demand that Philips may be able to cash out of more of its remaining position. It’s the largest European IPO this year.

The Dutch company has been working for almost two years to transition from a conglomerate with Lighting, Healthcare and Consumer businesses into one that’s solely devoted to HealthTech. Executing this IPO–as well as exiting its Lumileds business–are key to shedding its non-core businesses and doing so. Philips has said it will update Wall Street on its Lumileds plans next half.

Toward that aim, Philips has launched in Europe the first test for its hand-held acute care diagnostic device, Minicare I-20, after it received a CE mark. It’s also developing other tests for the system including for neuropsychiatric disorders with Johnson & Johnson ($JNJ) and a concussion test with San Diego, CA-based startup Banyan Biomarkers.

The first Minicare I-20 test measures the level of cardiac troponin I (cTnI), a protein that is excreted by the heart after a heart attack. It delivers test results that are comparable to lab testing, but in less than 10 minutes at the point of care. That’s expected to offer a faster route for physicians to determine treatment.

“The commercial launch of the Minicare I-20 system for cardiac troponin I testing represents a major milestone for us,” said Philips Handheld Diagnostics CEO Marcel van Kasteel in a statement. “Minicare I-20 is designed to help care providers reduce both the time-to-treatment and time-to-discharge of patients, thereby helping to reduce crowding in emergency departments and improve the utilization of hospital resources.”

Read More – Source: Philips launches first hand-held Dx for heart attack, as lighting IPO values biz at almost $4B

By: May 27, 2016 | By

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.